Drugs Receiving “Fast Track” Status Associated With Increased Safety Label Changes
A recent study examined whether expedited drug approvals have different rates of safety-related label changes compared with drugs approved through standard pathways.
A recent study examined whether expedited drug approvals have different rates of safety-related label changes compared with drugs approved through standard pathways.
Mavyret has been approved by the FDA to treat adults with certain types of chronic hepatitis C virus.
Radicava, given intravenously, slows physical decline in patients with ALS.
Ingrezza capsules were approved for treatment of adults with tardive dyskinesia.
This drug targets the PD-1/PD-L1 pathway and is the first sanctioned treatment in the United States.
This drug is designed to increase the absorption of water through the kidneys and decreasing urine production.
Oral tablets are to be used in combination with somatostatin analog therapy.
This drug is designed to stimulate secretions of intestinal fluid.